Insight Molecular Diagnostics Inc. Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option
Insight Molecular Diagnostics Inc. (IMDX) reported Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option of $58.50 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-16.
Discontinued › Notes
us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption · last filed 2024-04-16
- Insight Molecular Diagnostics Inc. increase (decrease) in fair value adjustments on other assets (liabilities) carried at fair value under fair value option for the quarter ending 2023-12-31 was $0.00.
- Insight Molecular Diagnostics Inc. increase (decrease) in fair value adjustments on other assets (liabilities) carried at fair value under fair value option for the quarter ending 2023-09-30 was $0.00.
- Insight Molecular Diagnostics Inc. increase (decrease) in fair value adjustments on other assets (liabilities) carried at fair value under fair value option for the quarter ending 2023-06-30 was $0.00.
- Insight Molecular Diagnostics Inc. increase (decrease) in fair value adjustments on other assets (liabilities) carried at fair value under fair value option for the quarter ending 2023-03-31 was $58.50K.
- Insight Molecular Diagnostics Inc. increase (decrease) in fair value adjustments on other assets (liabilities) carried at fair value under fair value option for fiscal 2023 was $58.50K, a 0.00% change from fiscal 2022.
- Insight Molecular Diagnostics Inc. increase (decrease) in fair value adjustments on other assets (liabilities) carried at fair value under fair value option for fiscal 2022 was $58.50K.
| Period end | Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 3 month | Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 6 month | Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 9 month | Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $0.00 derived: sum of 2 quarters · filed 2024-04-16 | $0.00 derived: sum of 3 quarters · filed 2024-04-16 | $58.50K 10-K · filed 2024-04-16 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $58.50K 10-Q · filed 2023-11-09 | $58.50K derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $58.50K 10-Q · filed 2023-08-10 | $58.50K derived: sum of 3 quarters · filed 2023-08-10 | $58.50K derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | $58.50K 10-Q · filed 2023-05-15 | $58.50K derived: sum of 2 quarters · filed 2023-05-15 | $58.50K derived: sum of 3 quarters · filed 2023-05-15 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-12 | $0.00 derived: sum of 2 quarters · filed 2023-04-12 | $58.50K 10-K · filed 2023-04-12 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $58.50K 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $58.50K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |